Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. Liu L, Zhao S, Li F et al (2016) Effect of 5α-reductase inhibitors on sexual function: a meta-analysis and systematic review of randomized controlled trials. J Sex Med 13:1297–1310
2. Total Patient Tracker (TPT) Years 2002-2009. SDI Vector One®. Data extracted May, 2011. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/020592Orig1s040s041OtherR.pdf
3. U.S. Food and Drug Administration. FDA Drug Safety Communication: 5-alpha reductase inhibitors (5-ARIs) may increase the risk of a more serious form of prostate cancer [Internet]. U.S. Food and Drug Administration, Silver Spring, c2013. Version 03/2013. 10]. http://www.fda.gov/Drugs/DrugSafety/ucm258314.htm
4. Ganzer CA, Jacobs AR, Iqbal F (2015) Persistent sexual, emotional, and cognitive impairment post-finasteride: a survey of men reporting symptoms. Am J Mens Health 9:222–228
5. Traish AM (2020) Post-finasteride syndrome: a surmountable challenge for clinicians. Fertil Steril 113:21–50
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献